Cargando…

Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease?

INTRODUCTION: Cognitive impairment is a highly prevalent non-motor feature of Parkinson’s disease (PD). A better understanding of the underlying pathophysiology may help in identifying therapeutic targets to prevent or treat dementia. This study sought to identify metabolic alterations in the prefro...

Descripción completa

Detalles Bibliográficos
Autores principales: Buard, Isabelle, Lopez-Esquibel, Natalie, Carey, Finnuella J., Brown, Mark S., Medina, Luis D., Kronberg, Eugene, Martin, Christine S., Rogers, Sarah, Holden, Samantha K., Greher, Michael R., Kluger, Benzi M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039312/
https://www.ncbi.nlm.nih.gov/pubmed/35496064
http://dx.doi.org/10.3389/fnhum.2022.809905
_version_ 1784694099726565376
author Buard, Isabelle
Lopez-Esquibel, Natalie
Carey, Finnuella J.
Brown, Mark S.
Medina, Luis D.
Kronberg, Eugene
Martin, Christine S.
Rogers, Sarah
Holden, Samantha K.
Greher, Michael R.
Kluger, Benzi M.
author_facet Buard, Isabelle
Lopez-Esquibel, Natalie
Carey, Finnuella J.
Brown, Mark S.
Medina, Luis D.
Kronberg, Eugene
Martin, Christine S.
Rogers, Sarah
Holden, Samantha K.
Greher, Michael R.
Kluger, Benzi M.
author_sort Buard, Isabelle
collection PubMed
description INTRODUCTION: Cognitive impairment is a highly prevalent non-motor feature of Parkinson’s disease (PD). A better understanding of the underlying pathophysiology may help in identifying therapeutic targets to prevent or treat dementia. This study sought to identify metabolic alterations in the prefrontal cortex (PFC), a key region for cognitive functioning that has been implicated in cognitive dysfunction in PD. METHODS: Proton Magnetic Resonance Spectroscopy was used to investigate metabolic changes in the PFC of a cohort of cognitively normal individuals without PD (CTL), as well as PD participants with either normal cognition (PD-NC), mild cognitive impairment (PD-MCI), or dementia (PDD). Ratios to Creatine (Cre) resonance were obtained for glutamate (Glu), glutamine and glutamate combined (Glx), N-acetylaspartate (NAA), myoinositol (mI), and total choline (Cho), and correlated with cognitive scores across multiple domains (executive function, learning and memory, language, attention, visuospatial function, and global cognition) administered to the PD participants only. RESULTS: When individuals retain cognitive capabilities, the presence of Parkinson’s disease does not create metabolic disturbances in the PFC. However, when cognitive symptoms are present, PFC Glu/Cre ratios decrease with significant differences between the PD-NC and PPD groups. In addition, Glu/Cre ratios and memory scores were marginally associated, but not after Bonferroni correction. CONCLUSION: These preliminary findings indicate that fluctuations in prefrontal glutamate may constitute a biomarker for the progression of cognitive impairments in PD. We caution for larger MRS investigations of carefully defined PD groups.
format Online
Article
Text
id pubmed-9039312
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90393122022-04-27 Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease? Buard, Isabelle Lopez-Esquibel, Natalie Carey, Finnuella J. Brown, Mark S. Medina, Luis D. Kronberg, Eugene Martin, Christine S. Rogers, Sarah Holden, Samantha K. Greher, Michael R. Kluger, Benzi M. Front Hum Neurosci Neuroscience INTRODUCTION: Cognitive impairment is a highly prevalent non-motor feature of Parkinson’s disease (PD). A better understanding of the underlying pathophysiology may help in identifying therapeutic targets to prevent or treat dementia. This study sought to identify metabolic alterations in the prefrontal cortex (PFC), a key region for cognitive functioning that has been implicated in cognitive dysfunction in PD. METHODS: Proton Magnetic Resonance Spectroscopy was used to investigate metabolic changes in the PFC of a cohort of cognitively normal individuals without PD (CTL), as well as PD participants with either normal cognition (PD-NC), mild cognitive impairment (PD-MCI), or dementia (PDD). Ratios to Creatine (Cre) resonance were obtained for glutamate (Glu), glutamine and glutamate combined (Glx), N-acetylaspartate (NAA), myoinositol (mI), and total choline (Cho), and correlated with cognitive scores across multiple domains (executive function, learning and memory, language, attention, visuospatial function, and global cognition) administered to the PD participants only. RESULTS: When individuals retain cognitive capabilities, the presence of Parkinson’s disease does not create metabolic disturbances in the PFC. However, when cognitive symptoms are present, PFC Glu/Cre ratios decrease with significant differences between the PD-NC and PPD groups. In addition, Glu/Cre ratios and memory scores were marginally associated, but not after Bonferroni correction. CONCLUSION: These preliminary findings indicate that fluctuations in prefrontal glutamate may constitute a biomarker for the progression of cognitive impairments in PD. We caution for larger MRS investigations of carefully defined PD groups. Frontiers Media S.A. 2022-04-12 /pmc/articles/PMC9039312/ /pubmed/35496064 http://dx.doi.org/10.3389/fnhum.2022.809905 Text en Copyright © 2022 Buard, Lopez-Esquibel, Carey, Brown, Medina, Kronberg, Martin, Rogers, Holden, Greher and Kluger. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Buard, Isabelle
Lopez-Esquibel, Natalie
Carey, Finnuella J.
Brown, Mark S.
Medina, Luis D.
Kronberg, Eugene
Martin, Christine S.
Rogers, Sarah
Holden, Samantha K.
Greher, Michael R.
Kluger, Benzi M.
Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease?
title Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease?
title_full Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease?
title_fullStr Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease?
title_full_unstemmed Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease?
title_short Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease?
title_sort does prefrontal glutamate index cognitive changes in parkinson’s disease?
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039312/
https://www.ncbi.nlm.nih.gov/pubmed/35496064
http://dx.doi.org/10.3389/fnhum.2022.809905
work_keys_str_mv AT buardisabelle doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease
AT lopezesquibelnatalie doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease
AT careyfinnuellaj doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease
AT brownmarks doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease
AT medinaluisd doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease
AT kronbergeugene doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease
AT martinchristines doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease
AT rogerssarah doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease
AT holdensamanthak doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease
AT grehermichaelr doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease
AT klugerbenzim doesprefrontalglutamateindexcognitivechangesinparkinsonsdisease